Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant

Journal of Clinical Investigation

Volumn 120, Issue 8, 2010, Pages 2715-2730

  Sun, Shihua ^a   Sprenger, Cynthia C T ^a   Vessella, Robert L ^a,b   Haugk, Kathleen ^b   Soriano, Kathryn ^a   Mostaghel, Elahe A ^a,c   Page, Stephanie T ^a   Coleman, Ilsa M ^c   Nguyen, Holly M ^a   Sun, Huiying ^d   Nelson, Peter S ^a,c   Plymate, Stephen R ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; BIOLOGICAL MARKER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER MODEL; CASTRATION; CONTROLLED STUDY; EXON; GENE DELETION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR XENOGRAFT;

ANDROGEN ANTAGONISTS; ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; MALE; MICE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA SPLICING; TRANSPLANTATION, HETEROLOGOUS;

EID: 77955296562     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI41824     Document Type: Article

References (52)

1. Scher H, Sawyers C. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23(32):8253-8261. (Pubitemid 46211563)
2. Huggins C, Hodges C. Studies on prostate cancer: effect of castration, estrogen, and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-297.
3. Culig Z, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994;54(20):5474-5478. (Pubitemid 24978134)
4. Marcelli M, et al. Androgen receptor mutations in prostate cancer. Cancer Res. 2000;60(4):944-994.
5. Peterziel H, et al. Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding. Int J Cancer. 1995;63(4):544-550.
6. Tilley W, Buchanan G, Hickey T, Bentel J. Mutations in the androgen receptor are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res. 1996;2(2):277-285. (Pubitemid 26074615)
7. Chen C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10(1):33-39. (Pubitemid 38524696)
8. Montgomery RB, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447-4454.
9. Mostaghel EA, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007;67(10):5033-5041.
10. Titus M, Schell M, Lih F, Tomer K, Mohler J. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res. 2005;11(13):4653-4657. (Pubitemid 41557182)
11. Reid AH, Attard G, Barrie E, de Bono JS. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol. 2008;5(11):610-620.
12. Steinkamp MP, et al. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res. 2009;69(10):4434-4442.
13. Guo Z, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009;69(6):2305-2313.
14. Hu R, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009;69(1):16-22.
15. Welsbie DS, et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res. 2009;69(3):958-966.
16. Mora G, Mahesh V. Autoregulation of androgen receptor in rat ventral prostate: involvement of c-fos as a negative regulator. Mol Cell Endocrinol. 1996;124(1-2):111-120. (Pubitemid 27042070)
17. Schmudde M, et al. Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. Cancer Lett. 2008;272(1):110-121.
18. Sonnemann J, Bumbul B, Beck JF. Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro. Mol Cancer Ther. 2007;6(11):2976-2984. (Pubitemid 350206776)
19. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta. 1991;1072(2-3):129-157. (Pubitemid 121007534)
20. Klampfer L. Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets. 2006;6(2):107-121.
21. Schreiber M, et al. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev. 1999;13(5):607-619. (Pubitemid 29131884)
22. Pandini G, et al. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res. 2005;65(5):1849-1857. (Pubitemid 40478613)
23. Mohler JL, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res. 2004;10(2):440-448. (Pubitemid 38173980)
24. Culig Z, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. Eur Urol. 1995;27(suppl 2):45-47.
25. Goel H, Languino L. Integrin signaling in cancer. Cancer Treat Res. 2004;119:15-31.
26. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. Androgen Receptor status of lymph node metastases from prostate cancer. Prostate. 1996;28(2):129-135. (Pubitemid 26066252)
27. Putz T, et al. Epidermal growth factor (EGF) receptor blockade inhibits the action of egf, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res. 1999;59(1):227-233. (Pubitemid 29062982)
28. Sadar M. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem. 1999;274(12):7777-7783. (Pubitemid 129518166)
29. Sadar M, Gleave M. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res. 2000;60(20):5825-5831.
30. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008;68(13):5469-5477.
31. Haelens A, Tanner T, Denayer S, Callewaert L, Claessens F. The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. Cancer Res. 2007;67(9):4514-4523. (Pubitemid 46815103)
32. O'Mahony OA, Steinkamp MP, Albertelli MA, Brogley M, Rehman H, Robins DM. Profiling human androgen receptor mutations reveals treatment effects in a mouse model of prostate cancer. Mol Cancer Res. 2008;6(11):1691-1701.
33. Centenera MM, Harris JM, Tilley WD, Butler LM. The contribution of different androgen receptor domains to receptor dimerization and signaling. Mol Endocrinol. 2008;22(11):2373-2382.
34. Alam TN, et al. Differential expression of CD44 during human prostate epithelial cell differentiation. J Histochem Cytochem. 2004;52(8):1083-1090. (Pubitemid 38982197)
35. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 2006;25(11):1620-1628.
36. Konrad L, et al. Alternative splicing of TGF-betas and their high-affinity receptors T beta RI, T beta RII and T beta RIII (betaglycan) reveal new variants in human prostatic cells. BMC Genomics. 2007;8:318. (Pubitemid 350104397)
37. Krick R, Jakubiczka S, Arnemann J. Expression, alternative splicing and haplotype analysis of transcribed testis specific protein (TSPY) genes. Gene. 2003;302(1-2):11-19. (Pubitemid 36078393)
38. Jackson-Cook C, Bae V, Edelman W, Brothman A, Ware J. Cytogenetic characterization of the human prostate cancer cell line P69SV40T and its novel tumorigenic sublines M2182 and M15. Cancer Genet Cytogenet. 1996;87(1):14-23. (Pubitemid 26113599)
39. Plymate S, Ware J, Tennant M, Thrasher J, Chatta K, Birnbaum R. The effect on the insulin-like growth factor system in human prostate epithelial cells of immortalization and transformation by simian virus-40 T antigen. J Clin Endocrinol Metab. 1996;81(10):3709-3716. (Pubitemid 26339943)
40. Bae V, Jackson-Cook C, Maygarden S, Chen J, Plymate S, Ware J. Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line. Prostate. 1998;34(4):275-282. (Pubitemid 28149872)
41. Plymate S, et al. Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors. Prostate. 2004;61(3):276-290. (Pubitemid 39350451)
42. Corey E, et al. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate. 2002;52(1):20-23. (Pubitemid 34553189)
43. Corey E, et al. LuCaP 35: A new model of prostate cancer progression to androgen independence. Prostate. 2003;55(4):239-246. (Pubitemid 36618182)
44. Corey E, Quinn J, Vessella R. A novel method of generating prostate cancer metastases from orthotopic implants. Prostate. 2003;56(2):110-114. (Pubitemid 41490327)
45. Wu JD, et al. Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors. Clin Cancer Res. 2006;12(20 pt 1):6153-6160.
46. Birnbaum R, Ware J, Plymate S. Insulin-like growth factor-binding protein-3 expression and secretion by cultures of human prostate epithelial cells and stromal fibroblasts. J Endocrinol. 1994;141(3):535-540. (Pubitemid 24218854)
47. Roudier MP, et al. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis. 2003;20(2):171-180.
48. Shariat SF, et al. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res. 2003;63(15):4662-4670.
49. Page S, et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab. 2006;91(10):3850- 3856. (Pubitemid 44536854)
50. Page ST, et al. Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites. Am J Physiol Endocrinol Metab. 2006;290(5):E856-E863.
51. Schayek H, Haugk K, Sun S, True LD, Plymate SR, Werner H. Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner. Clin Cancer Res. 2009;15(5):1558-1565.
52. Wu J, Haugk K, Plymate S. Activation of pro-apoptotic p38-MAPK pathway in the prostate cancer cell line M12 expressing a truncated IGF-IR. Horm Metab Res. 2003;35(11-12):751-757. (Pubitemid 38058179)